# SMMT — Summit Therapeutics · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** SMMT  
**Sources:** 20  
**Published:** 2026-11-13  
**Canonical:** https://app.k3vl4r.com/research/deep-research-smmt-summit-therapeutics-catalysts-narrative-risks-9645

---

## Overview

Summit Therapeutics (NASDAQ: SMMT), a Miami-based biotech, is approaching a binary regulatory milestone with its stock trading at roughly US$15.08 as of the November 12, 2026 close, down 9.41% that day [[13]](https://stockanalysis.com/stocks/smmt/forecast/), [[16]](https://stockanalysis.com/stocks/smmt/ratings/), [[17]](https://finance.yahoo.com/quote/SMMT/analysis/). Note that two other November references cite a higher price of about US$17.84 [[7]](https://www.msn.com/en-us/news/other/wall-street-analysts-see-a-6233-upside-in-summit-therapeutics-smmt-can-the-stock-really-move-this-high/ar-AA2h9cOi), [[8]](https://finance.yahoo.com/markets/stocks/articles/summit-therapeutics-smmt-stock-looks-002123453.html), which suggests the shares have fallen materially (roughly 15%+) in mid-November — plausibly due to de-risking ahead of the PDUFA, or profit-taking after the stock's multi-year run. Below is a point-in-time picture as of November 13, 2026.

## Recent catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-smmt-summit-therapeutics-catalysts-narrative-risks-9645 (free to sign up)._